

Artak Petrosyan, Julie Bellet (Clinical Research Department, Lille University Hospital, France); and Sandrine Brisset (Clinical Research Department, Amiens Picardie University Hospital, France).

DOI: 10.1097/ALN.0000000000003645

References

1. Kehlet H, Foss NB: Pleth variability index in orthopedic surgery: Comment. *ANESTHESIOLOGY* 2021; 134:500
2. Gelman S: Pleth variability index in orthopedic surgery: Comment. *ANESTHESIOLOGY* 2021; 134:501–2
3. Fischer MO, Lemoine S, Tavernier B, Bouchakour CE, Colas V, Houard M, Greub W, Daccache G, Hulet C, Compère V, Taing D, Lorne E, Parienti JJ, Hanouz JL: Optimization using the Pleth Variability Index (OPVI) Trial Group: Individualized fluid management using the Pleth Variability Index: A randomized clinical trial. *ANESTHESIOLOGY* 2020; 133:31–40
4. Fischer MO, Daccache G, Lemoine S, Tavernier B, Compère V, Hulet C, Bouchakour CE, Canevet C, Gérard JL, Guittet L, Lorne E, Hanouz JL, Parienti JJ: The OPVI trial – perioperative hemodynamic optimization using the plethysmographic variability index in orthopedic surgery: Study protocol for a multicenter randomized controlled trial. *Trials* 2015; 16:503
5. Fischer MO, Guinot PG, Biais M, Mahjoub Y, Mallat J, Lorne E; French Hemodynamic Team (FHT): A dynamic view of dynamic indices. *Minerva Anestesiol* 2016; 82:1115–21
6. Maheshwari K, Sessler DI: Goal-directed therapy: Why benefit remains uncertain. *ANESTHESIOLOGY* 2020; 133:5–7

(Accepted for publication November 11, 2020. Published online first on December 10, 2020.)

Postoperative Hypotension and Myocardial Injury: Comment

To the Editor:

We have read with great interest the observational cohort study “Postoperative Hypotension after Noncardiac Surgery and the Association with Myocardial Injury,” by Liem *et al.*¹ In this study the authors examined postoperative

hypotension after noncardiac surgery as a risk factor for myocardial injury by defining multiple mean arterial pressure (MAP) thresholds and different characterizations of blood pressure exposures. We commend the authors for further emphasizing the association between postoperative hypotension and myocardial injury and stressing the potential benefit of postoperative continuous blood pressure monitoring. May we ask the authors to provide some additional details that will help address some concerns and will better put their findings into clinical perspective? First, the secondary outcome of 30-day all-cause mortality was not compared between patients with *versus* patients without myocardial injury. May we kindly ask the authors to provide baseline characteristics including 30-day all-cause mortality stratified for myocardial injury and no myocardial injury? Second, the authors concluded that postoperative duration under a MAP threshold of 75 mmHg was associated with increased risk of myocardial injury. We are concerned that the corresponding figure 3 may lead some readers to falsely interpret the results, because the association between duration under a MAP threshold of 75 mmHg and myocardial injury was only significant for a duration of more than 635 min. Additionally, for a duration of more than 635 min under a MAP threshold of 75 mmHg, CIs are gradually increasing. Moreover, when comparing duration under MAP for five different thresholds, duration under a threshold of 75 mmHg did not remain significant. Please consider highlighting alternative thresholds that might be better supported by your data. Third, previous studies have additionally adjusted for use of cardiovascular medications before surgery (*i.e.*, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, calcium channel blocker, β -blocker, statin, diuretics, aspirin, oral anticoagulants).^{2–4} We are concerned that not adjusting for preoperative cardiovascular medication may have led to an overestimation of the association between hypotension and injury or death. Please provide a sensitivity analysis adjusting for those important confounders. This will help clinicians to further understand the impact of postoperative hypotension on myocardial injury.

Competing Interests

Dr. Mueller reports grants and nonfinancial support from the Swiss National Science Foundation (Bern, Switzerland), the Swiss Heart Foundation (Bern, Switzerland), the University Hospital Basel (Basel, Switzerland), Basel University (Basel, Switzerland), the Foundation for Cardiovascular Research Basel (Basel, Switzerland), Abbott (Baar, Switzerland), Beckman Coulter (Nyon, Switzerland), Idorsia (Basel, Switzerland), Novartis (Basel, Switzerland), Ortho Diagnostics (Zug, Switzerland), Quidel (San Diego, California), Roche (Basel, Switzerland), Siemens (Zuerich, Switzerland), Singulex (Basel, Switzerland), and BRAHMS (Hennigsdorf, Germany) outside the submitted work. The other authors declare no competing interests.

David Schulthess, M.D., Melissa Amrein, Ph.D., Noemi Glarner, M.D., Ph.D., Pedro Lopez-Ayala, M.D., Christian Mueller, M.D. Cardiovascular Research Institute Basel (CRIB) and University Hospital of Basel, University of Basel, Basel, Switzerland (D.S.). david.schulthess@usb.ch

DOI: 10.1097/ALN.0000000000003660

References

1. Liem VGB, Hoeks SE, Mol KHJM, Potters JW, Grüne F, Stolker RJ, van Lier F: Postoperative hypotension after noncardiac surgery and the association with myocardial injury. *ANESTHESIOLOGY* 2020; 133:510–22
2. van Waes JA, van Klei WA, Wijeyundera DN, van Wolfswinkel L, Lindsay TF, Beattie WS: Association between intraoperative hypotension and myocardial injury after vascular surgery. *ANESTHESIOLOGY* 2016; 124:35–44
3. Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A: Relationship between Intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac surgery: A retrospective cohort analysis. *ANESTHESIOLOGY* 2017; 126:47–65
4. Sessler DI, Meyhoff CS, Zimmerman NM, Mao G, Leslie K, Vásquez SM, Balaji P, Alvarez-Garcia J, Cavalcanti AB, Parlow JL, Rahate PV, Seeberger MD, Gossetti B, Walker SA, Premchand RK, Dahl RM, Duceppe E, Rodseth R, Botto F, Devereaux PJ: Period-dependent associations between hypotension during and for four days after noncardiac surgery and a composite of myocardial infarction and death: A substudy of the POISE-2 trial. *ANESTHESIOLOGY* 2018; 128:317–27

(Accepted for publication December 3, 2020. Published online first on December 31, 2020.)

Postoperative Hypotension and Myocardial Injury: Reply

In Reply:

We are more than happy to answer the questions Schulthess *et al.*¹ have, based on our previous publication.² The first question was to provide baseline characteristics of patients with and without myocardial

injury. Their second question was related to the exposure and the associated risk for myocardial injury. Schulthess *et al.* are correct that duration under a mean arterial pressure (MAP) threshold of 75 mmHg is only associated with myocardial injury for prolonged periods of time. To graphically represent the relation between length of hypotension and myocardial injury, we could have chosen a MAP target of 60 mmHg where all durations, above 1 h, show an increased risk for myocardial injury. However, we

Table 1. Baseline and Perioperative Characteristics of High-dependency Ward Patients, Stratified for Myocardial Injury

| | No Myocardial Injury (n = 1,472) | Myocardial Injury (n = 238) |
|---|-------------------------------------|--------------------------------|
| Patient characteristics | | |
| Age, yr | 70 [65, 75] | 74 [68, 79] |
| Male sex, n (%) | 823 (56) | 161 (68) |
| Procedural, n (%) | | |
| Emergency | 42 (3) | 33 (14) |
| High-risk | 384 (26) | 55 (23) |
| General anesthesia | 1,442 (98) | 229 (96) |
| Type of surgery, n (%) | | |
| General | 270 (18) | 38 (16) |
| Orthopedic | 167 (11) | 40 (17) |
| Urologic or gynecologic | 153 (10) | 22 (9) |
| Neurologic | 505 (34) | 27 (11) |
| Vascular | 225 (15) | 82 (34) |
| Other | 152 (10) | 29 (12) |
| Medical history, n (%) | | |
| Hypertension | 813 (55) | 175 (74) |
| Insulin-dependent diabetes mellitus | 144 (10) | 50 (21) |
| Chronic obstructive pulmonary disease | 236 (16) | 54 (23) |
| Myocardial infarction | 206 (14) | 83 (35) |
| Coronary artery disease | 265 (18) | 104 (44) |
| Congestive heart failure | 100 (7) | 48 (20) |
| Cerebrovascular disease | 234 (16) | 71 (30) |
| Renal failure | 53 (4) | 69 (29) |
| Peripheral artery disease | 115 (8) | 38 (16) |
| Preoperative medication, n (%) | | |
| β-blockers | 585 (40) | 137 (58) |
| Statins | 642 (44) | 147 (62) |
| Angiotensin converting enzyme-inhibitors | 345 (23) | 73 (31) |
| Angiotensin II antagonists | 273 (19) | 55 (23) |
| Calcium channel blockers | 281 (19) | 67 (28) |
| Diuretics | 448 (30) | 116 (49) |
| Aspirin | 397 (27) | 111 (47) |
| Oral anticoagulants | 202 (14) | 57 (24) |
| Preoperative | | |
| Hemoglobin, g/dl | 14 ± 2 | 13 ± 2 |
| Glomerular filtration rate, ml · min ⁻¹ · 1.73 m ⁻² | 75 [61, 87] | 50 [28, 77] |
| Heart rate, beats per min | 74 [66, 82] | 74 [66, 84] |
| MAP, mmHg | 97 [90, 105] | 94 [87, 101] |
| Intraoperative | | |
| Length of surgery, min | 242 [178, 326] | 210 [153, 296] |
| Estimated blood loss, ml | 300 [100, 650] | 250 [50, 700] |
| Postoperative | | |
| Peak high-sensitive troponin T, ng/l | 14 [9, 21] | 86 [62, 152] |
| Myocardial injury, n (%) | 0 | 238 (100) |
| 30-day mortality, n (%) | 30 (2) | 20 (8) |

MAP, mean arterial pressure.

Table 2. Univariate and Multivariate Associations of Postoperative Hypotension, Defined as Different Exposures, and Myocardial Injury

| Minutes below MAP, mmHg | Total (n = 1,710) | Myocardial Injury (n = 238) | Univariate Odds Ratio (95% CI) | Adjusted Odds Ratio* (95% CI) | Adjusted Odds Ratio* (95% CI) [Full Model]† | P Values |
|--|----------------------|--------------------------------|-----------------------------------|----------------------------------|---|----------|
| Intraoperative MAP < 65 | | | | | | |
| Reference (0) | 254 | 39 (15.35) | | | | |
| Q1: 1–8 | 377 | 52 (13.79) | 0.88 (0.56–1.39) | 0.92 (0.54–1.57) | 0.87 (0.51–1.49) | 0.599 |
| Q2: 9–22 | 370 | 49 (13.24) | 0.84 (0.53–1.33) | 1.18 (0.70–2.03) | 1.15 (0.67–1.98) | 0.624 |
| Q3: 23–53 | 351 | 44 (12.54) | 0.79 (0.50–1.26) | 1.28 (0.73–2.25) | 1.11 (0.63–1.98) | 0.713 |
| Q4: > 53 | 358 | 54 (15.08) | 0.98 (0.63–1.54) | 1.66 (0.93–3.00) | 1.36 (0.75–2.50) | 0.313 |
| Postoperative MAP < 75 | | | | | | |
| Reference (0) | 268 | 24 (8.96) | | | | |
| Q1: 1–86 | 361 | 40 (11.08) | 1.27 (0.75–2.18) | 1.19 (0.66–2.21) | 1.17 (0.64–2.17) | 0.621 |
| Q2: 87–312 | 360 | 59 (16.39) | 1.99 (1.22–3.35) | 1.75 (0.99–3.21) | 1.74 (0.97–3.19) | 0.069 |
| Q3: 313–635 | 360 | 45 (12.50) | 1.45 (0.87–2.48) | 1.42 (0.77–2.67) | 1.34 (0.72–2.55) | 0.363 |
| Q4: > 635 | 361 | 70 (19.39) | 2.45 (1.51–4.08) | 2.91 (1.60–5.46) | 2.69 (1.45–5.12) | 0.002 |
| Area under threshold mmHg · min | | | | | | |
| Intraoperative MAP < 65 | | | | | | |
| Reference (0) | 254 | 39 (15.35) | | | | |
| Q1: 1–32 | 366 | 48 (13.11) | 0.83 (0.53–1.32) | 0.93 (0.54–1.59) | 0.87 (0.51–1.50) | 0.619 |
| Q2: 33–108 | 362 | 49 (13.54) | 0.86 (0.55–1.37) | 1.18 (0.69–2.02) | 1.08 (0.63–1.86) | 0.789 |
| Q3: 109–279 | 364 | 42 (11.54) | 0.72 (0.45–1.15) | 1.13 (0.65–1.98) | 0.97 (0.55–1.72) | 0.915 |
| Q4: > 279 | 364 | 60 (16.48) | 1.09 (0.70–1.70) | 1.76 (1.01–3.12) | 1.44 (0.81–2.59) | 0.219 |
| Postoperative MAP < 75 | | | | | | |
| Reference (0) | 268 | 24 (8.96) | | | | |
| Q1: 1–337 | 361 | 42 (11.63) | 1.34 (0.80–2.30) | 1.22 (0.67–2.25) | 1.20 (0.66–2.22) | 0.563 |
| Q2: 338–1513 | 360 | 50 (13.89) | 1.64 (0.99–2.78) | 1.52 (0.85–2.79) | 1.49 (0.82–2.76) | 0.196 |
| Q3: 1514–4419 | 360 | 58 (16.11) | 1.95 (1.19–3.29) | 1.88 (1.04–3.48) | 1.83 (1.00–3.42) | 0.053 |
| Q4: > 4419 | 361 | 64 (17.73) | 2.19 (1.35–3.67) | 2.59 (1.41–4.88) | 2.36 (1.26–4.51) | 0.008 |
| Time-weighted average, mmHg | | | | | | |
| Intraoperative MAP < 65 | | | | | | |
| Reference (0) | 254 | 39 (15.35) | | | | |
| Q1: 0–0.14 | 364 | 44 (12.09) | 0.76 (0.48–1.21) | 0.93 (0.54–1.61) | 0.88 (0.51–1.54) | 0.661 |
| Q2: 1.14–0.46 | 364 | 49 (13.46) | 0.86 (0.54–1.36) | 1.14 (0.67–1.96) | 1.03 (0.60–1.79) | 0.921 |
| Q3: 0.46–1.12 | 364 | 44 (12.09) | 0.76 (0.48–1.21) | 1.16 (0.67–2.02) | 1.02 (0.58–1.79) | 0.943 |
| Q4: > 1.12 | 364 | 62 (17.03) | 1.13 (0.73–1.76) | 1.54 (0.90–2.67) | 1.25 (0.71–2.21) | 0.438 |
| Postoperative MAP < 75 | | | | | | |
| Reference (0) | 268 | 24 (8.96) | | | | |
| Q1: 0–0.29 | 361 | 37 (10.25) | 1.16 (0.68–2.01) | 1.07 (0.59–2.00) | 1.06 (0.58–1.97) | 0.858 |
| Q2: 1.29–1.33 | 360 | 56 (15.56) | 1.87 (1.14–3.16) | 1.74 (0.97–3.18) | 1.71 (0.95–3.14) | 0.078 |
| Q3: 2.33–3.67 | 360 | 55 (15.28) | 1.83 (1.12–3.10) | 1.82 (1.00–3.38) | 1.74 (0.95–3.28) | 0.077 |
| Q4: > 3.67 | 361 | 66 (18.28) | 2.27 (1.40–3.80) | 2.70 (1.48–5.09) | 2.51 (1.35–4.80) | 0.004 |

There were no significant interactions between postoperative and intraoperative hypotension within the models. Bonferroni correction was used to adjust for the three defined exposures for postoperative hypotension. $P < 0.05/3 = 0.017$ was considered statistically significant. MAP, mean arterial pressure.

*Multivariate logistic model adjusted for age, sex, high-risk surgery, emergency procedures, intraoperative hypotension, intra- and postoperative heart rate, previous history of hypertension, insulin-dependent diabetes mellitus, coronary artery disease, congestive heart failure, cerebrovascular disease, renal disease, estimated blood loss, length of surgery, and preoperative use of β -blockers, statins, angiotensin converting enzyme inhibitors, angiotensin II antagonists, calcium channel blockers, diuretics, aspirin, and oral anticoagulants; one observation deleted because of missingness. †Full model: Model with both intraoperative and postoperative exposures in the model (in quartiles).

have specifically chosen to report the highest threshold because this threshold was selected based on the figure in the supplemental digital content of the original article. Furthermore, we believe this threshold is relevant because the amount of time that was associated with myocardial injury (greater than 10h) can be easily reached during the first postoperative night. The final question was with regard to certain preoperative medication and the risk of confounding. In our analysis we used the widely accepted rule of 10 events per variable to prevent imprecise and

biased estimates in the logistic regression analysis. We therefore chose to adjust for the variables mostly associated with myocardial injury or hypotension. Sensitivity analysis including adjustment for the preoperative cardiovascular medication showed marginal differences in our results. Please find all the requested analysis in the tables 1–3.

Competing Interests

The authors declare no competing interests.

Table 3. Association of Postoperative Hypotension, as Duration under Multiple MAP Thresholds, and Myocardial Injury

| Postoperative MAP Thresholds | Duration under MAP Threshold (h) | Total (n = 1,710) | Myocardial Injury (n = 238) | Adjusted Odds Ratio* (95% CI)† [Full Model] | P Value‡ |
|------------------------------|----------------------------------|-------------------|-----------------------------|---|----------|
| MAP < 60 mmHg | 0 | 1,010 | 114 (11.29) | Ref | |
| | 0–1 | 466 | 70 (15.02) | 1.53 (1.04–2.26) | 0.030 |
| | 1–2 | 91 | 23 (25.27) | 2.73 (1.45–4.99) | 0.001 |
| | 2–4 | 76 | 16 (21.05) | 3.30 (1.57–6.64) | 0.001 |
| | > 4 | 67 | 15 (22.39) | 2.04 (0.93–4.28) | 0.065 |
| MAP < 65 mmHg | 0 | 693 | 74 (10.68) | Ref | |
| | 0–1 | 474 | 64 (13.50) | 1.47 (0.97–2.23) | 0.067 |
| | 1–2 | 153 | 26 (16.99) | 1.78 (0.97–3.16) | 0.055 |
| | 2–4 | 160 | 23 (14.37) | 1.81 (0.98–3.26) | 0.054 |
| | > 4 | 230 | 51 (22.17) | 3.01 (1.79–5.06) | < 0.001 |
| MAP < 70 mmHg | 0 | 466 | 49 (10.52) | Ref | |
| | 0–1 | 371 | 50 (13.48) | 1.25 (0.77–2.03) | 0.359 |
| | 1–2 | 174 | 16 (9.20) | 0.80 (0.39–1.56) | 0.527 |
| | 2–4 | 195 | 28 (14.36) | 1.28 (0.71–2.29) | 0.407 |
| | > 4 | 504 | 95 (18.85) | 2.19 (1.37–3.57) | 0.001 |
| MAP < 75 mmHg | 0 | 268 | 24 (8.96) | Ref | |
| | 0–1 | 285 | 32 (11.23) | 1.15 (0.61–2.19) | 0.662 |
| | 1–2 | 157 | 21 (13.38) | 1.53 (0.74–3.13) | 0.245 |
| | 2–4 | 178 | 21 (11.80) | 1.29 (0.63–2.61) | 0.482 |
| | > 4 | 822 | 140 (17.03) | 2.04 (1.19–3.64) | 0.012 |
| MAP < 80 mmHg | 0 | 153 | 17 (11.11) | Ref | |
| | 0–1 | 191 | 13 (6.81) | 0.52 (0.22–1.22) | 0.132 |
| | 1–2 | 122 | 18 (14.75) | 1.48 (0.66–3.36) | 0.344 |
| | 2–4 | 164 | 23 (14.02) | 1.20 (0.55–2.66) | 0.646 |
| | > 4 | 1080 | 167 (15.46) | 1.39 (0.75–2.73) | 0.319 |

There were no significant interactions between postoperative and intraoperative hypotension within the models. MAP, mean arterial pressure.

*Multivariate logistic model adjusted for age, sex, high-risk surgery, emergency procedures, intraoperative hypotension, intra- and postoperative heart rate, previous history of hypertension, insulin-dependent diabetes mellitus, coronary artery disease, congestive heart failure, cerebrovascular disease, renal disease, estimated blood loss, length of surgery, and preoperative use of β -blockers, statins, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, calcium channel blockers, diuretics, aspirin, and oral anticoagulants; one observation deleted because of missingness. †Bonferroni correction was used to adjust for the five defined MAP thresholds for postoperative hypotension. $P < 0.05/5 = 0.01$ was considered statistically significant.

Victor G. B. Liem, M.D., M.Sc., Sanne E. Hoeks, Ph.D., Felix van Lier, M.D., Ph.D. Erasmus University Medical Center, Rotterdam, The Netherlands (F.v.L.). F.vanlier@erasmusmc.nl

DOI: 10.1097/ALN.0000000000003659

References

- Schulthess D, Amrein M, Glarner N, Lopez-Ayala P, Mueller C: Postoperative hypotension and myocardial injury: Comment. *ANESTHESIOLOGY* 2021; 134:503–4
- Liem VGB, Hoeks SE, Mol KHJM, Potters JW, Grüne F, Stolker RJ, van Lier F: Postoperative hypotension after noncardiac surgery and the association with myocardial injury. *ANESTHESIOLOGY* 2020; 133:510–22

(Accepted for publication December 1, 2020. Published online first on December 31, 2020.)

Anesthesia and Circulating Tumor Cells: Comment

To the Editor:

With great interest we have read the article by Hovaguimian *et al.*¹ regarding the effect of different anesthesia drugs (sevoflurane or propofol) on the number of circulating tumor cells in patients undergoing breast cancer surgery. We appreciate and congratulate the authors for setting up a meaningful randomized, controlled trial and sharing such useful findings. There are, however, two important points of concern.

First of all, the study used a mixed Poisson model. However, we noted that the first quartile of circulating tumor cell count results at all time points was zero, and the median was also zero